Abstract
Adipokines are proteins produced by white adipose tissue, which is an active secretory organ. Regulation of immune and inflammatory responses is among the multiple physiological processes involving adipokines. Leptin, adiponectin and resistin are the most extensively studied adipokines. Leptin may promote inflammation by inducing Th1 phenotype development, whereas adiponectin may combat inflammation by reducing the production of pro-inflammatory cytokines. Resistin belongs to a family of proteins found in foci of inflammation, where they contribute to the inflammatory response. All three adipokines have been detected in synovial fluid from joints affected with the inflammatory disease rheumatoid arthritis (RA) or the degenerative disease osteoarthritis (OA). Recent evidence points to involvement of leptin in RA and OA and indicates that adiponectin and/or resistin mediate inflammation in arthritis. Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases.
Keywords: Adipokines, leptin, adiponectin, resistin, rheumatoid arthritis, osteoarthritis
Current Medicinal Chemistry
Title: The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases
Volume: 14 Issue: 10
Author(s): Eric Toussirot, Gerald Streit and Daniel Wendling
Affiliation:
Keywords: Adipokines, leptin, adiponectin, resistin, rheumatoid arthritis, osteoarthritis
Abstract: Adipokines are proteins produced by white adipose tissue, which is an active secretory organ. Regulation of immune and inflammatory responses is among the multiple physiological processes involving adipokines. Leptin, adiponectin and resistin are the most extensively studied adipokines. Leptin may promote inflammation by inducing Th1 phenotype development, whereas adiponectin may combat inflammation by reducing the production of pro-inflammatory cytokines. Resistin belongs to a family of proteins found in foci of inflammation, where they contribute to the inflammatory response. All three adipokines have been detected in synovial fluid from joints affected with the inflammatory disease rheumatoid arthritis (RA) or the degenerative disease osteoarthritis (OA). Recent evidence points to involvement of leptin in RA and OA and indicates that adiponectin and/or resistin mediate inflammation in arthritis. Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases.
Export Options
About this article
Cite this article as:
Toussirot Eric, Streit Gerald and Wendling Daniel, The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases, Current Medicinal Chemistry 2007; 14 (10) . https://dx.doi.org/10.2174/092986707780362826
DOI https://dx.doi.org/10.2174/092986707780362826 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Effects of Novel Standardized Platelet Rich Plasma Releasates on Knee Osteoarthritic Chondrocytes and Cartilage in vitro
Current Pharmaceutical Biotechnology Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major etabolitie, A77 1726
Drug Metabolism Letters Editorial (Thematic Issue: Current Perspectives and Challenges in Design, Chemistry and Pharmacology of Opioids)
Current Pharmaceutical Design Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Emerging Pathophysiological Targets of Psoriasis for Future Therapeutic Strategies
Infectious Disorders - Drug Targets Construction of an Anti-IL-1β scfv and TNFRI Fusion Protein and Its Therapeutic Effect on RA Mice Model
Current Pharmaceutical Biotechnology Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Role of IL-17F in the Pathogenesis of Psoriasis
Current Immunology Reviews (Discontinued) Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Gray Scale and Power Doppler Ultrasonographic Findings in the Assessment of Disease Activity and Their Correlation with Disease Activity Parameters in Rheumatoid Arthritis
Current Rheumatology Reviews